Amedisys Inc (AMED) Lowered to Neutral at Mizuho

Paterniano Del Favero
Luglio 28, 2017

BlackRock Inc. boosted its stake in shares of Amedisys Inc (NASDAQ:AMED) by 2,877.7% during the first quarter, according to its most recent filing with the SEC.

A number of institutional investors have recently made changes to their positions in the company. Thrivent Financial for Lutherans increased its position in shares of Amedisys by 6.2% in the fourth quarter. The stock exchanged hands 2.5 Million shares versus average trading capacity of 347.05 Million shares. CIBC Asset Management Inc bought a new stake in Amedisys during the second quarter worth about $230,000. First Midwest Bank Trust Division raised its stake in shares of Amedisys by 3.0% in the first quarter. Redmile Group LLC purchased a new position in shares of Amedisys during the first quarter valued at about $247,000. State of Alaska Department of Revenue now owns 3,080 shares of the health services provider's stock valued at $157,000 after buying an additional 70 shares during the period.

Currently Amedisys Inc (NASDAQ:AMED)'s shares owned by insiders are 1.8%, whereas shares owned by institutional owners are 89.5%. Mizuho upgraded Amedisys Inc (NASDAQ:AMED) on Tuesday, January 19 to "Buy" rating. The firm has a market cap of $1.58 billion, a PE ratio of 34.80 and a beta of 0.94. Amedisys has a 1-year low of $34.58 and a 1-year high of $65.91. $50.33's average target is 1.99% above currents $49.35 stock price.

Amedisys Inc (NASDAQ:AMED) issued its earnings results on Wednesday. The health services provider reported $0.62 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.50 by $0.12.

On the other hand the company has Relative Strength Index (RSI 14) of 18.46 along with Average True Range (ATR 14) of 2.23, Consequently Amedisys Inc (NASDAQ:AMED)'s weekly and monthly volatility is 3.39%, 2.77% respectively. The business had revenue of $378.80 million during the quarter, compared to the consensus estimate of $380.80 million. During the same quarter in the prior year, the business earned $0.42 EPS. Amedisys's quarterly revenue was up 5.0% on a year-over-year basis. On average, analysts expect that Amedisys will post $2.08 EPS for the current year.

COPYRIGHT VIOLATION WARNING: "Amedisys Inc (NASDAQ:AMED) Position Increased by BlackRock Inc." was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. and worldwide copyright and trademark legislation. The correct version of this piece can be read at

Several research analysts have weighed in on AMED shares. Royal Bank Of Canada restated a "hold" rating and issued a $56.00 price target on shares of Amedisys in a report on Monday, June 5th. Finally, Zacks Investment Research lowered Amedisys from a buy rating to a hold rating in a report on Tuesday, May 2nd. Mizuho cut Amedisys from a "buy" rating to a "neutral" rating and set a $50.00 price target for the a report on Wednesday. BidaskClub lowered Amedisys from a strong-buy rating to a buy rating in a report on Wednesday, July 12th. Stephens increased their target price on shares of Amedisys from $50.00 to $54.00 and gave the stock an equal weight rating in a research report on Thursday, May 4th. Five research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus price target of $56.50. Also, Director Jake L. Netterville sold 10,000 shares of the firm's stock in a transaction that occurred on Friday, May 12th. The shares were sold at an average price of $60.00, for a total transaction of $600,000.00. Following the completion of the purchase, the director now directly owns 13,331 shares of the company's stock, valued at approximately $795,727.39. Also, Director Bruce D. Perkins acquired 500 shares of the company's stock in a transaction dated Thursday, May 25th. Thrivent Financial for Lutherans now owns 15,133 shares of the health services provider's stock worth $645,000 after buying an additional 880 shares in the last quarter. Following the sale, the insider now owns 13,018 shares of the company's stock, valued at $763,115.16. The disclosure for this sale can be found here. Insiders sold 56,828 shares of company stock valued at $3,350,922 over the last ninety days. Ameritas Investment Partners Inc. bought a new stake in Amedisys during the first quarter worth about $123,000. The Company's divisions are Home Health, Hospice, Personal Care and Other. Mizuho now has $50.00 target price on the health services provider's stock.

Altre relazioni OverNewsmagazine

Discuti questo articolo